Photo of Vivek Subbiah from businesswire.com
Aug 27, 2023, 18:58
Vivek Subbiah: The 3rd KRAS G12C kid on the block.
According to Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute:
“Just published NEJM – the 3rd KRAS G12C kid on the block. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
NSCLC, ORR= 53.4%
mPFS = 13.1 months
Colorectal cancer= 29.1%
mPFS= 5.6 months”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 24, 2024, 00:40
Dec 24, 2024, 00:34
Dec 24, 2024, 00:32
Dec 24, 2024, 00:30
Dec 24, 2024, 00:27
Dec 24, 2024, 00:24
Dec 24, 2024, 00:16